Over the past three months, Shockwave continued to ride a big wave of momentum with new product launches, inclusions in new journal articles, a pulse-racing presence at EuroPCR and more. The launch of Shockwave L6 Peripheral IVL Catheter in the U.S. came with physician-led case reviews, Q&As and more valuable content that demonstrate the big impact it can make in large peripheral vessels. We also turned up the heat at EuroPCR in Paris, where we showcased live cases, hosted an engaging symposium and participated in PCR TV interviews - all while focusing heavily on the European launch of our Shockwave C2+ Coronary IVL Catheter, which includes 50% more pulses than the original Shockwave C2. Dive right in and catch the wave of excitement in the latest issue of the PulsePoint newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
New Medicare Severity Diagnosis Related Groups (MS-DRGs) With Increased Payments Replace Temporary Payment Pathway for Coronary IVL Procedures Within the Hospital Inpatient Setting
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Shockwave C2,
Reimbursement
It is a privilege to be recognized as one of Fast Company’s 2023 Best Workplaces for Women Innovators!
Read More
Topics:
IVL Technology,
SWAV News
Introducing the Shockwave Medical Direct Sales Team in the Great White North!
Read More
Topics:
IVL Technology,
SWAV News
EuroPCR 2023 was a real blast for Shockwave Medical! Three sponsored sessions, two featured live cases,one interview on PCR TV andmany, many invaluable conversations at our booth. Thank you to all of you who attended for making this our best EuroPCR so far!
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2,
Coronary Conferences
2023 was off to a shockingly great start! We were thrilled to acquire Neovasc, a company with a first-of-its-kind technology to address refractory angina, and are looking forward to driving value for physicians and improving the lives of an underserved patient population. The excitement for our new peripheral product, Shockwave L6, was electrifying and has continued to make waves across the U.S. Shockwave IVL and Coronary IVL became listed by SCAI as a potential therapy option across all U.S. cath labs regardless of surgical backup status. As always, we were further confirming the efficacy and safety of Shockwave IVL across different calcium morphologies through new publications. We highlight these topics and more in our latest PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
We asked Prof. James Spratt and Dr. Simon Wilson to share their IVL journey since the launch of Shockwave C2 five years ago and their initial experience with the new Shockwave C2+. Regardless of the physicians experience, the overall opinion is the same: “IVL is quick to learn, easy to use, very safe, and effective across a broad range of calcium types that other technologies can’t compete with. It has changed the landscape for calcium modification and the new Shockwave C2+ catheter continues to expand physicians ability to deal effectively and safely with severe calcium in a broader range of patients.” Read more below:
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Shockwave C2
In the latest ChalkTalk episode, we sat down with Dr. Jonathan Hill, Royal Brompton Hospital, London, to have a discussion about his 5-year journey with Coronary IVL. Being involved in the first Disrupt CAD clinical studies and one of the first commercial users of the technology, he has vast experience, which he has translated into many best practices, including creating the “pulse management strategy” approach to energy distribution in the artery. In our conversation, Dr. Hill speaks to some of the most memorable moments in his interventional career, his insights into the new Shockwave C2+ catheter and his outlook on EuroPCR 2023 and beyond. We hope you enjoy this personal insights and don’t miss our latest blogpost for more information on Shockwave IVL at EuroPCR 2023 https://blog.shockwavemedical.com/europcr-2023
Read More
Topics:
Coronary IVL,
IVL Technology,
Shockwave C2
